ReachMD

Dr. Mark Carvlin is the Vice President for Clinical Affairs of NanoScan Imaging. He has held posts with Bracco Diagnostics and Bristol Myers Squibb, and he was a former officer of the Medical Imaging Contrast Media Association. He was a member of the faculty of the Department of Radiology at the University of Pennsylvania and at Georgetown University. His research has focused on using medical imaging in conjunction with diagnostic and therapeutics to evaluate the functional status of organ systems in health and disease. He is currently the Chief Operating Officer of Atherochem, a development-stage company with novel biopharmaceuticals for the treatment of coronary heart disease caused by atherosclerosis. In addition, he is the founder and Managing Director of Intellectual Capital Development Co, a strategic management consulting company.